Citius Pharmaceuticals Inc expected to post a loss of 4 cents a share - Earnings Preview

Citius Pharmaceuticals

08/05/2023 13:36

* Citius Pharmaceuticals Inc  CTXR.OQ   CTXR.O  is expected
to show no change in quarterly revenue when it reports 
results on May 10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Citius
Pharmaceuticals
Inc is for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $6​, above​ its last closing price
of $1.28. ​​​

This summary was machine generated May 8 at 12:35 GMT.  All
figures in US dollars  unless otherwise stated